Spartacus-Biomed a R&D Company

 

The world global market for in vitro diagnostic tests  is predicted to reach  a compound annual growth rate (CAGR) of 12 % over the next five-year period.

 

Spartacus-Biomed business model is focused on biomarkers which are estimated to peak annual turnovers of up to 800 M€ in Europe. Indeed,  the biomarkers are being increasingly used to aid for diagnosis, to a much lesser extend for prognosis and to identify sub-populations with differing benefit-risk ratios. 

 

Spartacus-Biomed  is providing novel Biomarkers that will equip  physicians with tools to improve the early diagnosis, to identify patients at risk of developing diseases, and to characterize patient subsets with a greater likelihood of response to  preventive therapies.

 

This project is funded by Occitanie district.

 

Spartacus-Biomed a R&D Company

 

The world global market for in vitro diagnostic tests  is predicted to reach  a compound annual growth rate (CAGR) of 12 % over the next five-year period.

 

Spartacus-Biomed business model is focused on biomarkers which are estimated to peak annual turnovers of up to 800 M€ in Europe. Indeed,  the biomarkers are being increasingly used to aid for diagnosis, to a much lesser extend for prognosis and to identify sub-populations with differing benefit-risk ratios. 

 

Spartacus-Biomed  is providing novel Biomarkers that will equip  physicians with tools to improve the early diagnosis, to identify patients at risk of developing diseases, and to characterize patient subsets with a greater likelihood of response to  preventive therapies.

 

This project is funded by Occitanie district.